The GLP-1 Economy: A Market Map for Media Buyers

How big is the GLP-1 market really, and who owns each layer?

No single verified figure for total GLP-1 market size survives close checking, so treat any specific dollar total in an affiliate deck as a claim to verify, not a fact to repeat. What's checkable is the layer structure. Novo Nordisk and Eli Lilly manufacture the only FDA-approved molecules — semaglutide, tirzepatide, liraglutide — and sit at the top, protected by patents and by Meta's rule that only pharmaceutical manufacturers, certified online pharmacies and certified telehealth providers may advertise prescription drugs at all, per Meta's Transparency Center Advertising Standards on Drugs and Pharmaceuticals.

Below manufacturers sits telehealth: prescribers who write scripts and, increasingly, dispense compounded or branded product directly. FDA's March 2026 wave of 30 warning letters to telehealth companies over misleading GLP-1 marketing shows how much revenue moved through this layer; regulators don't send that many letters to a category worth nothing. Compounding pharmacies sit under telehealth, filling the prescriptions. Both the tirzepatide and semaglutide shortages that let 503A and 503B facilities compound freely have since been declared resolved, cutting off the legal basis most compounders relied on.

At the bottom sits the layer affiliates touch most: dietary-supplement brands selling 'GLP-1 support' formulas, and gray-market peptide resellers labeling product 'research use only.' Neither owns real GLP-1 revenue; both rent the language, and both draw disproportionate enforcement attention relative to their actual share of the dollars, precisely because the branded layer above them is hard to reach and the supplement layer is easy to cite in a warning letter.

Where do affiliates actually fit in the GLP-1 value chain?

Affiliates sit almost entirely outside the prescription-drug layer and almost entirely inside two adjacent lanes: telehealth lead generation and supplement CPA. Meta restricts prescription-drug ads to pharmaceutical manufacturers, certified online pharmacies and certified telehealth providers holding active LegitScript status, a bar most individual affiliates cannot clear on their own ad accounts. Google applies a comparable certification requirement before an advertiser can even keyword-target semaglutide or tirzepatide by name, per Google Ads' healthcare and prescription-drug policies.

Most buyers who want in on the telehealth side run as a sub-affiliate inside a certified brand's own program, where the brand carries the LegitScript certification and the compliance risk while the affiliate supplies traffic and gets paid per qualified lead or completed prescription. Scouting which telehealth brands are actually running paid creative, and where, is exactly the kind of intelligence work an ad spy feed is built for.

The supplement CPA lane carries none of the LegitScript requirement, because the product itself isn't a prescription drug. That's precisely why so much GLP-1-adjacent affiliate volume lives here instead of in telehealth: lower compliance overhead, faster account approval, and a payout structure that doesn't require proving pharmacy licensure to a network before your first payment clears.

Why did nutra offers rebrand themselves around GLP-1 language?

Nutra offers rebranded around GLP-1 language because 'Ozempic alternative' and 'GLP-1 support' angles converted better than generic weight-loss copy the moment the drug entered everyday conversation, and the category chased the term faster than regulators could respond. That chase is now colliding with enforcement on two separate fronts at once.

On the FDA side, naming a prescription GLP-1 drug inside supplement labeling or marketing is itself treated as evidence of an implied disease claim under 21 CFR 101.93(g)(2), which converts a dietary supplement into an unapproved new drug in FDA's eyes regardless of the 'not evaluated by the FDA' disclaimer printed underneath it. The regulation specifically flags claims that a product 'augments' or substitutes for a therapy, or references an ingredient 'well known to consumers' for treating a disease — language a lot of 'natural Ozempic' copy fits uncomfortably well.

On the ad-platform side, Google's Unapproved substances policy bans products that imply they are as effective as prescription drugs regardless of any claims of legality, which is the exact rule a 'natural Ozempic' headline runs into. FTC's Gut Check guidance adds a second layer: claims of substantial weight loss achieved without any change in diet or exercise sit on the explicit list of claims FTC states cannot be true, disclaimer or not.

Which GLP-1 adjacent categories are growing versus peaking?

Compounded semaglutide and tirzepatide are the categories peaking hardest, right as most of the affiliate infrastructure built to sell them was finished. The shortages that gave 503A and 503B pharmacies legal cover to compound copies of the approved drugs have both been declared resolved — tirzepatide on December 19, 2024, semaglutide on February 21, 2025 — and FDA's enforcement-discretion wind-down for both has since lapsed.

Growing instead: unapproved research peptides sitting in regulatory limbo, and the NAD+ and longevity-adjacent stack one step removed from GLP-1 itself. BPC-157 lost its Category 2 compounding listing in April 2026 through a procedural nomination withdrawal, not a safety clearance, and it still isn't legally compoundable because it fits none of the three statutory bases for 503A compounding. A July 2026 FDA advisory committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, epitalon and semax to the compoundable list, but an advisory vote isn't agency action, and it changes no law by itself.

Buyers scouting which of these categories is actually running paid creative right now don't rely on guesswork. The same discipline used to vet ad intelligence worth paying for in CIS markets applies here: pull live creative, check the landing page against current platform policy, and confirm a claim before committing budget to it.

How do telehealth payouts compare with supplement payouts here?

Telehealth GLP-1 offers generally pay more per conversion than supplement CPA, but exact payout figures move network to network and need checking against the current payout page before anyone builds a media plan around them. The structural difference explains why the gap exists: telehealth pays for a completed prescription or subscription start, a higher-value, higher-friction action, while supplement CPA pays for a lower-ticket checkout that converts faster and scales with less friction.

That headline payout gap may overstate telehealth's real advantage once you account for what happened to optimization data. Meta began restricting health-and-wellness advertisers from sharing lower-funnel conversion events through its Business Tools starting in January 2025, with affected brands losing Conversions API access or full lower-funnel optimization, a change trade press reported and Meta has never documented on a first-party policy page. A telehealth advertiser that can't feed Meta's algorithm real purchase data is optimizing partly blind on the platform that usually drives the cheapest volume, which narrows the practical earnings gap even where the headline payout row stays wide.

Supplement offers keep a separate scale advantage regardless of payout size: no LegitScript gate, no health-data restriction, and account approval that doesn't require proving pharmacy licensure to anyone. For a buyer optimizing for volume rather than per-unit payout, that combination often beats a nominally richer telehealth payout row over a full month of spend.

Which regulatory shifts could reprice the whole wave overnight?

Four decisions currently in progress could reprice this entire market before they're finalized, and none of them has landed yet. The biggest is FDA's proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list entirely, announced April 30, 2026 with Commissioner Marty Makary stating outsourcing facilities cannot lawfully compound these drugs absent a clear clinical need once FDA-approved versions are available. The comment period closed June 29, 2026, and FDA has stated only that it will consider the comments before a final determination.

The Fifth Circuit is also still deciding Outsourcing Facilities Association v. FDA, No. 25-10758, the semaglutide compounding case, with Novo Nordisk as intervenor and the federal government's brief filed in early 2026. A ruling either direction changes what every compounding-linked telehealth affiliate program can legally advertise. Watch the opposite direction too: FDA's advisory committee is scheduled to revisit five more peptides around February 2027, and its July 2026 votes recommending BPC-157 and five others, while non-binding, signal where the agency's own scientific advisors actually lean.

State attorneys general are moving faster than any federal court. Alabama's November 2025 suit against Aurora IV and Wellness ended in a permanent closure and a surrendered nursing license by January 2026, and Connecticut's December 2025 cease-and-desist letters target corporate-practice-of-medicine violations directly, a legal theory that doesn't wait on FDA at all and that new statutes in Oregon and California are actively expanding. Meta, meanwhile, says it's expanding advertiser verification toward 90% of ad revenue by the end of 2026, up from 70%, concentrated on the highest-risk categories, health and weight loss chief among them.

Tracking which of these lands first matters more than picking a side today, because each one reprices a different layer of the chain: courts hit compounders, state AGs hit clinics, Meta hits ad accounts. Buyers who stay ahead of this tend to do it through recurring reading rather than one-time research, which is the logic behind curated lists like the newsletters media buyers actually open in 2026 instead of a single saved article.

Where does the money move next as injectables go mainstream?

Money moves toward whichever layer carries the least unresolved legal risk at any given moment, and right now that's pulling volume away from compounding and toward two poles: manufacturer-authorized telehealth on one side, supplement and lifestyle adjacents on the other. Retatrutide is the clearest signal of where the branded pipeline goes next. Eli Lilly's Phase 3 TRIUMPH-1 program reported roughly 28% to 30% average weight loss at 80 weeks on the 12 mg dose, with a marketing application anticipated around Q1 2027, meaning every current US sale of it is still the sale of an unapproved drug.

Expect telehealth affiliate programs to consolidate around brands holding LegitScript certification and manufacturer authorization rather than around compounding pharmacies, since the legal ground under independent compounders keeps eroding. Enforcement-discretion windows have already lapsed, and FDA's proposed 503B bulks exclusion would remove the remaining legal basis for outsourcing facilities to compound these three molecules at all if finalized. Supplement adjacents built around side-effect management — fiber, protein, electrolyte and gut-health formulas positioned for people already on the drugs — sit on cleaner legal ground than 'alternative' framing, provided the copy never names the prescription drug.

Geographically, the United States, Canada and New Zealand remain the only markets where Meta permits prescription-drug advertising at all, which pushes any buyer chasing GLP-1-adjacent volume outside that footprint toward supplement and lifestyle framing exclusively. Buyers who already maintain a working list of GEOs worth targeting for other verticals should treat GLP-1-adjacent supplement offers as a separate geo exercise entirely, since the drug-ad geo-fence Meta enforces doesn't apply to a fiber capsule.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Daily Intel research methodology, Does the Attribution Setting Change Delivery, or Only Reporting?, Will a Fresh Ad Account Fix a CPA Problem? Usually Not, Cost Per Result Goal on a Fixed-Payout Offer: Where to Set It, Value Optimization for Supplement Offers With Upsells and Rebills, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.